Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)
Johnson & Johnson's (JNJ) quarterly Income from Non-Controlling Interests came in at -$339.0 million in Q3 2012.
Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends
Johnson & Johnson has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$339.0 million for Q3 2012.
- Income from Non-Controlling Interests for Q3 2012 came in at -$339.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was -$339.0 million (changed N/A YoY), and the FY2012 annual result was -$339.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests came in at -$339.0 million for Q3 2012 at Johnson & Johnson.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$339.0 million in Q3 2012 to a low of -$339.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | 415.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | -339.00 Mn |